Europe
RefluxStop™ is CE marked in Europe. It is currently available in:
- Germany
- United Kingdom
- Switzerland
- Spain
- Italy
- France
- Austria
- Sweden
- Norway
Press Releases
2026
Implantica announces landmark RefluxStop[® ]study of 602 patients across 22 European centers, with up to 6.75-year follow-up, published in Nature’s Scientific Reports
21.04.2026
| Other press releases
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux – a condition affecting over 1 billion people worldwide – announces the publication of the largest and first-of-its-kind real-world safety outcomes study of RefluxStop®. The study demonstrating excellent long-term results has been published in Scientific Reports, part of the prestigious Nature portfolio of journals.
Implantica publishes Year-end Report, January – December 2025 (Q4)
25.02.2026
| Regulatory
RefluxStop® US Launch Coming Closer, pending FDA approval
Implantica presents the Year-end Report (Q4 2025) on February 25 at 15:00 CET
18.02.2026
| Other press releases
Implantica AG (publ) invites investors to a presentation of the Year-end Report (Q5 2025) at 15:00 CET on February 25. The Year-end Report (Q4 2025) will be published at 8:00 a.m. CET on the same day.
Implantica announces major public tender wins in Italy securing over EUR 1.2 million funding for RefluxStop®
27.01.2026
| Other press releases
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux (GERD), a treatment field with 1 billion sufferers, announces over €1.2 million public healthcare funding from two new multi-year public tender approvals in Italy for its groundbreaking acid reflux procedure, RefluxStop®.
2025
Implantica strengthens market expansion as Italy’s leading Careggi University Hospital in Florence introduces RefluxStop®
10.12.2025
| Other press releases
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux (GERD), a treatment field with 1 billion sufferers, announces adoption of RefluxStop at the world-renowned Careggi University Hospital.
RefluxStop® "Best in Class" at Japan Foregut Conference as 5-Year Data and Extensive Safety Cohort is Presented to 120 Leading Surgeons
25.11.2025
| Other press releases
Implantica AG (publ), a medtech company at the forefront of introducing advanced technology into the body, announced today that its innovative device, RefluxStop®, was a central highlight of the recent Japan Foregut Conference. The exclusive event, organized by Dr. Yasuhiro Fujiwara of the Department of Gastroenterology at Osaka Municipal University, brought together approximately 120 top surgeons and GI experts focusing on cutting-edge foregut disease treatments.
RefluxStop® takes center stage at 2025 European Foregut Society meeting
11.11.2025
| Other press releases
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces RefluxStop® was a great success at the European Foregut Society (EFS) Annual Meeting in Athens last week.
Implantica publishes Interim Report January – September 2025 (Q3)
31.10.2025
| Regulatory
RefluxStop® Nears FDA Approval – Strong Momentum Toward US Market Entry
Implantica presents the third quarter 2025 on October 31 at 15:00 CET
27.10.2025
| Other press releases
Implantica AG (publ) invites investors to a presentation of the third quarter 2025 at 15:00 CET on October 31. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day.
Implantica completes FDA 100-Day Meeting for RefluxStop® PMA application
13.10.2025
| Other press releases
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces the successful completion of its 100-Day meeting with the U.S. Food and Drug Administration (FDA) regarding the Premarket Approval (PMA) application for RefluxStop®.